{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"42.3","upperLimit":"79.3","value":"62.1"},{"groupId":"OG001","lowerLimit":"47.3","upperLimit":"99.7","value":"87.5"},{"groupId":"OG002","lowerLimit":"29.8","upperLimit":"74.3","value":"52.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"21"}],"units":"Participants"}],"description":"Defined as the proportion of participants who achieved the best objective response rate (complete response (CR) + partial response (PR)) as determined by modified Acquired Immunodeficiency Syndrome Clinical Trials Group (ACTG) criteria Analyzed using Clopper-Pearson 95% confidence intervals.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants enrolled into Cohort 4 and participants with evaluable HIV associated Kaposi sarcoma enrolled into Cohorts 1-3, who receive pembrolizumab IV over 30 minutes on day 1. Participants continue receiving their recommended combination antiretroviral therapy per established regimen. Cycles repeat every 21 days for up to 2 years or 35 doses in the absence of disease progression or unacceptable toxicity. Participants undergo physical examination and blood sample collection, and may undergo CT or PET/CT. Participants may also undergo biopsies during screening and on study.\n\nAntiretroviral Therapy: Given PO\n\nBiopsy: Undergo biopsy\n\nBiospecimen Collection: Undergo blood sample collection\n\nComputed Tomography: Undergo CT or PET/CT\n\nPembrolizumab: Given IV\n\nPositron Emission Tomography: Undergo PET/CT","id":"OG000","title":"Kaposi Sarcoma Cohort (Pembrolizumab and cART)"},{"description":"Treatment naïve participants enrolled into Cohort 4 and treatment naïve participants with evaluable HIV associated Kaposi sarcoma enrolled into Cohorts 1-3, who receive pembrolizumab IV over 30 minutes on day 1. Participants continue receiving their recommended combination antiretroviral therapy per established regimen. Cycles repeat every 21 days for up to 2 years or 35 doses in the absence of disease progression or unacceptable toxicity. Participants undergo physical examination and blood sample collection, and may undergo CT or PET/CT. Participants may also undergo biopsies during screening and on study.\n\nAntiretroviral Therapy: Given PO\n\nBiopsy: Undergo biopsy\n\nBiospecimen Collection: Undergo blood sample collection\n\nComputed Tomography: Undergo CT or PET/CT\n\nPembrolizumab: Given IV\n\nPositron Emission Tomography: Undergo PET/CT","id":"OG001","title":"Treatment Naïve Kaposi Sarcoma Cohort (Pembrolizumab and cART)"},{"description":"Previously treated participants enrolled into Cohort 4 and previously treated participants with evaluable HIV associated Kaposi sarcoma enrolled into Cohorts 1-3, who receive pembrolizumab IV over 30 minutes on day 1. Participants continue receiving their recommended combination antiretroviral therapy per established regimen. Cycles repeat every 21 days for up to 2 years or 35 doses in the absence of disease progression or unacceptable toxicity. Participants undergo physical examination and blood sample collection, and may undergo CT or PET/CT. Participants may also undergo biopsies during screening and on study.\n\nAntiretroviral Therapy: Given PO\n\nBiopsy: Undergo biopsy\n\nBiospecimen Collection: Undergo blood sample collection\n\nComputed Tomography: Undergo CT or PET/CT\n\nPembrolizumab: Given IV\n\nPositron Emission Tomography: Undergo PET/CT","id":"OG002","title":"Previously Treated Kaposi Sarcoma Cohort (Pembrolizumab and cART)"}],"paramType":"NUMBER","populationDescription":"Analysis is based on all participants who have received at least one dose of study treatment. Participants with missing outcomes considered nonresponders. Participants without progression were censored at the last disease assessment date.","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Objective Response Rate (Partial Response + Completion Response)(Kaposi Sarcoma Cohort)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}